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The silent epidemic of COPD in Africa
Chronic obstructive pulmonary disease (COPD) is the 
third leading cause of death worldwide.1 It is one of the 
most common non-communicable diseases, aﬀ ecting 
329 million people, and this number is likely to be an 
underestimate. The global economic cost of COPD is 
US$2·1 trillion.2 Yet it remains almost unknown in Africa.
The prevalence of COPD in sub-Saharan Africa has 
been poorly studied. A meta-analysis3 of nine cross-
sectional studies (ﬁ ve from South Africa, two from 
Nigeria, one from Malawi, and one from Cape Verde) 
reported a prevalence ranging from 4·1% to 24·8%, 
depending on which diagnostic criterion was used. 
Of the nine studies, only one used population-based 
representative sampling and an internationally 
recognised case deﬁ nition, whereas the other studies 
lacked robust designs and had inconsistent diagnostic 
criteria. Another meta-analysis4 of an additional four 
studies from Africa reported that the prevalence of 
COPD varied widely depending on whether spirometry 
was used or not. The eight studies that deﬁ ned COPD 
on the basis of symptoms reported a mean prevalence 
of 4·0% (range 2·1–8·9), whereas the ﬁ ve that used 
spirometry reported a mean prevalence of 13·4% 
(9·4–22·1).
One of the main reasons why COPD prevalence 
studies are rare is the general lack of standardised 
epidemiological instruments and the need to do 
good quality post-bronchodilator spirometry, which 
requires considerable expertise and experience.5 
Studies that use symptom-based questionnaires 
lack suﬃ  cient sensitivity and speciﬁ city. Moreover, 
considerable controversy exists about which spirometric 
criterion should be used to deﬁ ne COPD: a ﬁ xed post-
bronchodilator FEV1 to FVC ratio of 0·7, or a FEV1 to FVC 
ratio less than the lower limit of normal. Each criterion 
has advantages and disadvantages, but the absence 
of an agreed standard has created confusion among 
epidemiologists wanting to study COPD prevalence.5
In The Lancet Global Health, Frederik van Gemert and 
colleagues6 present results of a cross-sectional study of 
COPD prevalence in 588 people in the Masindi district 
of Uganda, with COPD deﬁ ned by post-bronchodilator 
spirometry. This study is one of the ﬁ rst in sub-
Saharan Africa to use a robust sampling strategy and 
an internationally accepted diagnostic method and 
criterion. The prevalence of COPD was 16·2%. The 
investigators also report that the prevalence of COPD 
did not diﬀ er between men and women, around 40% 
of patients with COPD were aged 30–40 years, 31% of 
men and 74% of women with COPD had never smoked, 
nearly all individuals with and without COPD had been 
exposed to biomass smoke.
Smoke from biomass fuel is an important risk factor 
for COPD. From a global perspective, it might be more 
important than tobacco smoking.7 In the study by van 
Gemert and colleagues,6 93% of the study population 
used biomass fuel for cooking, as in most African 
countries. Women spent 3–5 h cooking with prolonged 
exposure to biomass smoke, often in poorly ventilated 
kitchens. This behaviour could explain why COPD is as 
common in women as in men, despite less smoking 
among women. Exposure to biomass smoke since 
childhood also explains why 40% of people with COPD 
in Uganda were young (30–40 years). In high-income 
countries, COPD prevalence studies traditionally include 
adults older than 40 years, because 15–20 years of 
exposure to tobacco smoke is needed before COPD 
begins to manifest.
Wheeze is a common symptom in patients with asthma 
and an uncommon symptom in COPD caused by tobacco 
smoke. The high prevalence of wheeze in this study 
suggests that COPD caused by biomass smoke might be a 
diﬀ erent phenotype than COPD caused by tobacco smoke. 
Biomass COPD mainly aﬀ ects airways, whereas tobacco 
smoke aﬀ ects both airways and lung parenchyma.8
What do these observations mean for countries in 
sub-Saharan Africa? van Gemert and colleagues have 
shown that high quality studies of COPD prevalence can 
be done with locally trained paramedical ﬁ eld workers. 
COPD seems to be highly prevalent in Africa, yet remains 
almost unknown. It seems to aﬀ ect mainly people aged 
30–40 years and the major risk factors are tobacco 
smoking and biomass smoke exposure, although other 
risk factors, such as poverty, poor nutrition, history 
of lung tuberculosis, or HIV infection, might also be as 
important. More studies are needed to understand the 
true burden of COPD in Africa and the risk factors for 
the disease. However, improved surveillance is merely 
the ﬁ rst step in addressing COPD in sub-Saharan Africa.9 
African health-care providers, including doctors, should 
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be taught how to address COPD eﬀ ectively; at present, 
diagnosis and treatment are grossly inadequate.10 
Health-care policy makers in sub-Saharan Africa need 
to take notice of the silently growing epidemic of COPD 
and start taking measures to both prevent and treat 
COPD eﬀ ectively, before it gets out of hand.
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